Related Experiment Video
Updated: Jul 9, 2026
11:42
Lentivirus Production
Published on: October 2, 2009
[A novel system for producing lentiviral vectors].
Qiang Ma1, Ming Li, Wen-Qi Dong
1College of Biotechnology, Southern Medical University, Guangzhou 510515, China.
Sheng Wu Gong Cheng Xue Bao = Chinese Journal of Biotechnology
|December 7, 2007
Summary
Researchers developed a novel poxviral/lentiviral hybrid system for enhanced lentiviral vector production. This new system achieves significantly higher titers, offering a promising basis for industrial applications in gene therapy.
Area of Science:
- Molecular Biology
- Virology
- Biotechnology
Context:
- Lentiviral vectors are crucial tools for gene delivery in research and therapy.
- Current lentiviral vector production systems face limitations in titer and scalability.
- Recombinant vaccinia viruses offer a powerful platform for expressing foreign genes.
Purpose:
- To establish a novel cell culture system for high-titer lentiviral vector production.
- To utilize recombinant vaccinia viruses as helper systems for lentiviral vector generation.
- To enhance the efficiency and yield of lentiviral vector manufacturing.
Summary:
- A hybrid system was developed using BHK21 cells co-transfected with lentiviral plasmids (pVECRNA, pGAGPOL, pVSVG) and infected with vaccinia virus vTF-3.
- The system successfully produced lentiviral vectors in the cell culture supernatant, confirmed by RT-PCR and Western blot.
- Real-time PCR detected approximately 1.17 x 10^12 copies/mL of lentiviral vector RNA, and flow cytometry measured titers up to 1.3 x 10^8 transduction units/mL.
Impact:
- The developed system achieved titers one order of magnitude higher than classical methods.
- This novel poxviral/lentiviral hybrid system represents a significant advancement in lentiviral vector production efficiency.
- The findings provide a foundation for the future industrial-scale development and application of lentiviral vectors.
